Abstract:Purpose: This review article summarizes the pathophysiological aspects of interleukins (ILs) including IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, and IL-10 in pancreatic cancer (PC). Methods: Science Direct, PubMed, and Google Scholar were used for the literature review. The search was conducted until August 12, 2024, and particular keywords such as "Pancreatic Cancer," "Interleukins," "Pathophysiological Aspects," "Immunosuppression," "Invasiveness," and "Metastasis" were used. Focusing on interleukins related to pancreatic cancer, 61 original studies were included: 32 studies for human patients, 16 studies for animal models, and 13 studies for both animal models and human patients. All types of PC were considered. The timeframe of 1991 to 2024 was chosen for clinical studies. Results: In epithelial pancreatic tumors, IL-1 is a major inflammation factor. Serum concentrations of soluble interleukin-2-receptor were considerably greater in patients with PC and chronic pancreatitis than in healthy individuals. In comparison to controls, pancreatic cancer patients had considerably greater levels of macrophage colony-stimulating factor and significantly lower levels of stem cell factor and IL-3. The tissues and cells of pancreatic cancer have higher concentrations of IL-4 receptors. IL-5 has a role in the accumulation of pancreatic fibrosis. For individuals with pancreatic ductal adenocarcinoma (PDAC), a high serum level of IL-6 may be a separate risk factor for the development of widespread liver metastases. PDAC patients' peripheral blood mononuclear cells exhibit a substantial upregulation of IL-7 receptor. The role of IL-8 in the growth and spread of PC in humans. The miR-200a/β-catenin axis may be the mechanism by which IL-9 stimulates the proliferation and metastasis of PC cells. Blocking IL-10 in the local microenvironment appears to result in a significant reversal of tumor-induced immunosuppression. Conclusion: The article concludes that interleukins 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 played significant roles in the pathogenesis of PC.

Exploring the role of interleukin 11 in cancer progression, patient survival, and therapeutic insights

Interleukin 11 (IL-11): Role(s) in Breast Cancer Bone Metastases

IL-11 signaling as a therapeutic target for cancer

More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer

High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.

Molecular Pathways: IL11 as a Tumor-Promoting Cytokine—Translational Implications for Cancers

Upregulation of IL-11, an IL-6 Family Cytokine, Promotes Tumor Progression and Correlates with Poor Prognosis in Non-Small Cell Lung Cancer

Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy

Update on development of interleukin-11

Interleukin-11/IL-11 Receptor Promotes Glioblastoma Cell Proliferation, Epithelial–Mesenchymal Transition, and Invasion

Emerging roles for IL-11 in inflammatory diseases

Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies

Enhancing antitumor immunity and achieving tumor eradication with IL11RA mRNA immunotherapy

Interleukin-11 Is the Dominant IL-6 Family Cytokine during Gastrointestinal Tumorigenesis and Can Be Targeted Therapeutically

The role of interleukin-6 classic and trans-signaling and interleukin-11 classic signaling in gastric cancer cells

The Contradictory Role of Interleukin-33 in Immune Cells and Tumor Immunity.

IL-11 mediates the Radioresistance of Cervical Cancer Cells via the PI3K/Akt Signaling Pathway

Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment

57: EVALUATION OF THE CIRCULATING LEVELS OF IL-12 AND IL-33 IN PATIENTS WITH BREAST CANCER: INFLUENCES OF THE TUMOR STAGES AND CYTOKINE GENE POLYMORPHISMS

Tumor-related interleukins: old validated targets for new anti-cancer drug development

Role of Interleukins in Pancreatic Cancer: A Literature Review